Should I Buy EWTX? EWTX 2026 Analysis

Should You Buy Edgewise Therapeutics Inc (EWTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

29.100

1 Day change

7.02%

52 Week Range

30.250

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now for an impatient trader: near-term momentum is weakening (down day + bearish MACD), and there are no near-term news catalysts.
Upside exists longer-term based on largely bullish Street targets, but key clinical readouts that could re-rate the stock appear months/quarters away.
Intellectia Proprietary Trading Signals
- AI Stock Picker: No signal on given stock today.
- SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: Moving averages are structurally bullish (SMA_5 > SMA_20 > SMA_200), but momentum is deteriorating short-term: MACD histogram -0.0844 and negatively expanding.
RSI: RSI(6) at 47.9 (neutral) → no oversold bounce signal.
Levels: Pivot 28.712 (price ~28.48 is slightly below pivot). Near support S1 27.498 (next S2 26.747). Overhead resistance R1 29.927 then R2 30.678.
Interpretation: The bigger trend looks constructive, but the stock is currently in a short-term pullback/soft patch; without a catalyst, it’s more likely to chop between ~27.5–30.0 than trend hard upward immediately.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Put/call OI ratio 0.15 is very call-heavy (bullish positioning).
Liquidity/Confirmation: Today’s options volume is extremely light (total volume ~4; put volume 0), so sentiment signal is not strongly confirmed by activity.
Volatility: IV(30d) ~~72 with **low IV rank/percentile (~~16–18)** → options imply relatively muted forward volatility vs its own history (HV is very high ~121), suggesting the market isn’t pricing an imminent big move.

Technical Summary

Sell

Buy

Positive Catalysts

- Clinical program optimism from Wall Street: multiple firms remain bullish on EDG-7500 in HCM with differentiation potential.
- Call-heavy options open interest suggests traders are leaning bullish in positioning.
- Longer-horizon catalysts: additional meaningful trial data (e.g., fuller 12-week data referenced for Q2 2026) could move the stock if positive.

Neutral/Negative Catalysts

- No news in the past week → limited event-driven upside right now.
- Safety overhang debate: at least one major firm highlights lingering questions (e.g., atrial fibrillation/titration concerns) that may not be resolved until later, controlled data.
- Near-term price action weak: -3.95% regular-session drop plus bearish/expanding negative MACD histogram.
- No notable recent insider/hedge fund accumulation trends; no recent congress trading data available (and no politician activity indicated).

Financial Performance

Latest quarter: 2025/Q3 (development-stage profile)
Revenue: 0 (no commercial revenue yet).
Loss trend improving modestly: Net income -40.7M (loss) improved ~19% YoY; EPS -0.39 improved ~8% YoY.
Takeaway: fundamentals are still driven by clinical progress and cash burn management; the quarter shows incremental improvement, but not a near-term driver for a fast price pop.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent rating/target trend: predominantly bullish stance maintained/raised into late-2025.
JPMorgan: Overweight; target raised to $34 (Nov 2025) and later commentary remained constructive on trial trajectory.
Truist / H.C. Wainwright: Buy with higher targets ($46 and $42 respectively) following Phase 2 updates.
Stifel: Hold, emphasizing unresolved safety/differentiation questions and viewing major conviction-building catalysts as farther out.
Wall Street pro view (pros/cons): Pros = perceived efficacy/differentiation potential in HCM; Cons = safety/titration questions and longer timeline to definitive Phase 3 clarity.

9 Analyst Rating

Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 38.14 USD with a low forecast of 16 USD and a high forecast of 51 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

1 Hold

0 Sell

Strong Buy

Current: 27.190

Low

Averages

38.14

High

Current: 27.190

Low

Averages

38.14

High

JPMorgan

Overweight

maintain

AI Analysis

2025-12-26

Reason

JPMorgan

Price Target

AI Analysis

2025-12-26

maintain

Overweight

Reason

JPMorgan was "encouraged" by the latest updates from Edgewise Therapeutics' ongoing phase 2 CIRRUS-HCM trial for EDG-7500 in obstructive HCM and nonobstructive HCM, which the firm sees reinforcing the "overall intriguing product profile" as a potential future treatment option for patients. The firm, which views EDG-7500 as on the "right track," thinks the full 12 week data from Part D due in Q2 of 2026 will be "more meaningful" in terms of EDG-7500's potential, as well as provide more information around dose optimization in both the oHCM and nHCM patient populations, the analyst tells investors. JPMorgan has an Overweight rating on Edgewise shares.

Truist

Buy

maintain

$46

2025-12-24

Reason

Truist

Price Target

$46

2025-12-24

maintain

Buy

Reason

Truist keeps a Buy rating and $46 price target on Edgewise Therapeutics following the company's updates from Phase 2 EDG-7500 trial in Hypertrophic Cardiomyopathy, or HCM. Edgewise reported data from both 25mg dose as well as interim data from part D of the study, and the firm remains bullish of the opportunity for EDG-7500 in both obstructive HCM and non-obstructive HCM given signs of efficacy in both patient groups, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for EWTX

Unlock Now

EWTX Should I Buy

EWTX Should I Buy

Should You Buy Edgewise Therapeutics Inc (EWTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch